The study comparison found substantially and significantly higher proportions of AR101-treated patients were able to tolerate clinically meaningful quantities of peanut protein compared to patients in the placebo arm at the double-blind, placebo-controlled food challenge (DBPCFC) that occurred at the end of the study. Overall safety was similar between the two patient populations, and the frequency of adverse events decreased in the fixed therapeutic dosing period compared to the dose escalation period.
“I’m encouraged to see that, across two robust and rigorously conducted clinical trials, the efficacy and safety of AR101 was consistent showing that treatment resulted in patients tolerating higher quantities of peanut protein while also confirming that the frequency of adverse events – while mostly mild or moderate – decreased during the therapeutic dosing period across both studies,” said
Across both studies:
- The median tolerated dose of peanut protein increased from 10 mg to 1000 mg between the entry and exit food challenges.
- Approximately two-thirds of patients tolerated 600 mg and over half tolerated 1,000 mg in the exit food challenge.
- Treatment emergent adverse events (TEAEs) that arose during in-clinic dose escalation visits occurred shortly after dose administration – typically within 30 minutes – and were transient in nature, generally resolving within 60 minutes.
- The frequency of TEAEs decreased in the therapeutic 300 mg/day AR101 dosing period compared with the dose escalation period.
One observed difference between the two studies was the use of epinephrine to treat TEAEs. In PALISADE, approximately 14.0% of patients were administered epinephrine whereas in ARTEMIS, 6.8% of the patients were administered epinephrine, probably reflecting practice differences between
AR101 is an investigational biologic drug for use during oral immunotherapy to reduce the incidence and severity of allergic reactions following exposure to peanuts. The Biologics License Application (BLA) for AR101 is under review by the
The international, randomized, double-blind, placebo-controlled phase 3 PALISADE (Peanut Allergy oral Immunotherapy Study of AR101 for Desensitization) trial evaluated the efficacy and safety of AR101 in patients with peanut allergy. PALISADE was conducted at 66 sites in 10 countries in
Patients enrolled in PALISADE underwent a dose escalation period of approximately 22 weeks to reach a therapeutic dose of 300 mg per day of AR101 or placebo, then continued with the daily therapeutic dose at 300 mg per day of AR101 or placebo for approximately six months. At that point, patients underwent an exit DBPCFC, which tested consecutive doses of 3, 10, 30, 100, 300, 600 and 1,000 mg of peanut protein, given 20 to 30 minutes apart, and associated with only mild symptoms. Both the entry and exit DBPCFCs used an independent, blinded assessor. Following the completion of the exit DBPCFC, patients were unblinded and eligible to rollover or crossover into the follow-on ARC004 clinical trial, as appropriate.
The randomized, double-blind, placebo-controlled phase 3 ARTEMIS (AR101 Trial in Europe Measuring oral Immunotherapy Success) trial evaluated the efficacy and safety of AR101 in peanut-allergic patients ages 4 to 17 years who were enrolled at 18 sites in seven European countries (
AR101 is an investigational, peanut-derived, biologic drug candidate for use in oral immunotherapy in patients with peanut allergy. The drug candidate, which is manufactured in accordance with current Good Manufacturing Practices (cGMP), delivers a daily dose of peanut protein with a consistent protein profile, analyzed to ensure reliable major allergen content. The amount of active ingredient in each AR101 capsule is controlled to ensure minimal variability of allergen content across doses of a given strength. AR101 is administered as an oral powder in graduated doses in pull-apart capsules or foil-laminate sachets. The contents are mixed thoroughly with a few spoonfuls of age-appropriate, unheated food of the patient’s choice.
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Aimmune’s expectations regarding the potential benefits of AR101; and Aimmune’s expectations regarding potential applications of the CODIT™ approach to treating potentially life-threatening food allergies. Risks and uncertainties that contribute to the uncertain nature of the forward-looking statements include: the expectation that Aimmune will need additional funds to finance its operations; the unpredictability of the regulatory process; the possibility that Aimmune’s or any of its collaborative partners’ clinical trials will not be successful; Aimmune’s dependence on the success of AR101; Aimmune’s reliance on third parties for the manufacture of Aimmune’s product candidates; possible regulatory developments in
This press release concerns AR101 and AR201, product candidates that are under clinical investigation. Neither AR101 nor AR201 has been approved for marketing by the